Physician profile
Timothy E Knox
NPI 1700974821
$8,010.44
in general payments reported to CMS, 2019-2025
16 companies · $1,039 in 2025
The $1,039 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,374 · 2020: $585 · 2021: $800 · 2022: $968 · 2023: $917 · 2024: $1,328 · 2025: $1,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,283.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,667.12 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $970.67 | 2019-2022 | |
| Janssen Biotech, INC. | $945.91 | 2024-2025 | Tremfya, Stelara |
| Pfizer INC. | $646.99 | 2019-2021 | |
| Amgen INC. | $614.15 | 2019-2024 | Krystexxa |
| Glaxosmithkline, LLC. | $557.55 | 2019-2024 | Shingrix |
| Horizon Therapeutics Plc | $248.98 | 2023 | Krystexxa |
| Lilly USA, LLC | $233.10 | 2024-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $231.38 | 2022-2024 | Wegovy, Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.46 | 2019-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $172.83 | 2019 | |
| Gilead Sciences, INC. | $125.00 | 2024 | Veklury |
| Vanda Pharmaceuticals INC. | $115.32 | 2025 | Fanapt |
| Amarin Pharma, INC. | $103.26 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $99.29 | 2021-2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $77.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Knox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.